Navigation Links
CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
Date:2/13/2008

ATLANTA, Feb. 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the Roth Capital Partners 20th Annual OC Growth Stock Conference, February 19, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, Calif.

D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present Tuesday, February 19 at 8:30 a.m., Pacific Time.

CryoLife's live presentation may be accessed through its Web site, http://www.cryolife.com, on the Investor Relations page. An archived copy of the presentation will be available for 90 days on the same Web site.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for its CryoValve(R) SG pulmonary human heart valves, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

For additional information about the Company, visit CryoLife's Web Site: http://www.cryolife.com.
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
2. CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
3. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
4. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
5. CryoLife Announces Record Preservation Services and Product Revenues for 2007
6. CryoLife to Present at OneMedPlace Finance Forum
7. CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
8. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
9. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
10. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
11. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... The Thomas Brain Health Center ... groundbreaking pilot study to see if early Alzheimer’s ... little as three to six months. , The ... medicine—will aggressively target and simultaneously treat the numerous ... brain. These include oxidative stress, neuroinflammation, mitochondrial dysfunction, ...
(Date:4/23/2015)... 23, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology and medical ... and the United States , ... the first quarter of 2015 after the New York ... will be Thursday morning, May 14, 2015 Shanghai time). ...
(Date:4/23/2015)... 2015 Glemser Technologies ... EMC® Enterprise Content Division (ECD) Certified Solution Partner ... Documentum® for Life Sciences Solution Suite . The ... capabilities to provide life sciences companies of all ... The EMC Documentum Solution Suite offers four modules: ...
(Date:4/23/2015)... 23, 2015 ReliantHeart's HeartAssist5® Ventricular Assist ... flow through the device) in real time, and this ... world’s leading provider of Machine to Machine (M2M) communications ... Flow via VADLink.com can be monitored by ... drop in flow below a minimum threshold, the patient ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... Data Presented Today at American Society of Clinical Oncology ... Therapeutics, Inc. today presented data demonstrating the use of ... cetuximab (ERBITUX(R)) on the colorectal cancer cells of individual ... the 54 primary colorectal cultures tested, eight percent were ...
... of response up to week 26 in moderate to ... infliximab. , , CHICAGO, June 1 New ... the Digestive Disease Week meeting demonstrate that Cimzia(R) (certolizumab ... week 26 for adult patients suffering from moderate to ...
... SOUTH PLAINFIELD, N.J., June 1 PTC Therapeutics, Inc. ... as Vice President of Commercial Operations. In this ... President, Commercial, and will be responsible for PTC,s patient ... reimbursement. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ...
Cached Biology Technology:Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 2Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 4Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 5Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 6Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 7Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 8Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 9Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 10PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations 2
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... School of Medicine of the University of Southern California ... female sex hormone, activates genes in breast-cancer cells. Greater ... lead to new treatments for the disease. ... Keck School,s Department of Biochemistry and Molecular Biology, was ...
... The TWAS 22nd General Meeting will take place on ... Theoretical Physics (ICTP), home to the Academy,s secretariat. TWAS,s ... by Romain Murenzi, executive director of TWAS; Fernando Quevedo, ... Affairs, Italy; and Jacob Palis, TWAS President, will highlight ...
... PARIS, Nov. 15, 2011 DigitalPersona, ... and endpoint protection solutions, today announced the availability ... biometric device manufacturers and solution providers. FingerJet OEM ... along with fast one-to-many identification and one-to-one verification. ...
Cached Biology News:USC researchers discover key aspect of process that activates breast cancer genes 2TWAS 22nd General Meeting in Trieste 2DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers 2DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers 3
...
Ezrin/Radixin/Moesin Antibody...
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... ADAMTS16 ( Abpromise for all ... Synthetic peptide based on the ... the amino acid sequence is proprietary) ... 170690 SWISS Protein ...
Biology Products: